Shizuoka, Japan

Takanori Nihira

This inventor holds 1 USPTO granted patent. Top assignees: Japan as Represented by Director General of Agency of Industrial Science, Meiji Seika Kaisha, Ltd.. Active years: 2000.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Takanori Nihira: Innovator in Enzyme Technology

Introduction

Takanori Nihira is a notable inventor based in Shizuoka, Japan. He has made significant contributions to the field of enzyme technology, particularly through his work on mesophilic xylanases. His innovative approach has led to the development of a patent that showcases his expertise and dedication to advancing scientific knowledge.

Latest Patents

Takanori Nihira holds a patent for mesophilic xylanases. This invention is crucial for various applications in biotechnology and industrial processes, highlighting his role as a key player in enzyme research. The patent demonstrates his ability to create solutions that address specific challenges in the industry.

Career Highlights

Throughout his career, Takanori Nihira has worked with prominent organizations, including Meiji Seika Kaisha, Ltd. and the Japan Agency for Industrial Science and Technology. His experience in these institutions has allowed him to collaborate with other experts and contribute to significant advancements in his field.

Collaborations

Takanori has collaborated with notable colleagues such as Masako Mizuno and Toshiaki Kono. These partnerships have enriched his research and expanded the impact of his work in enzyme technology.

Conclusion

Takanori Nihira's contributions to the field of enzyme technology through his patent on mesophilic xylanases and his collaborations with esteemed colleagues underscore his importance as an inventor. His work continues to influence the industry and inspire future innovations.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…